A multi-center, open-label extension study to examine the safety and tolerability of ACP-103 in the treatment of psychosis in Parkinson's disease

Trial Profile

A multi-center, open-label extension study to examine the safety and tolerability of ACP-103 in the treatment of psychosis in Parkinson's disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Dec 2015 to 1 Jan 2018.
    • 17 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 06 Aug 2015 According to an Acadia Pharmaceuticals media release, new data from this study were published in the Journal of the American Medical Directors Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top